Mafenide
Description
Name: Mafenide
Type: small molecule
Groups: approved
Indication: Mafenide is indicated in the treatment of severe burns.
Accession Number: DB06795 ( DB06795)
Description: Mafenide is a sulfonamide-type medication used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.
Structure:
Prescription Products:
Generic Prescription Products:
Over the Counter Products: Not Available
Prescription Products:
Generic Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: approved
Indication: Mafenide is indicated in the treatment of severe burns.
Accession Number: DB06795 ( DB06795)
Description: Mafenide is a sulfonamide-type medication used to treat severe burns. It acts by reducing the bacterial population present in the burn tissue and promotes healing of deep burns.
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Sulfamylon | cream | 85 mg/g | topical | 08-12-2006 | US | |
| Sulfamylon | powder, for solution | 50 g/1 | topical | 05-06-1998 | US | |
| Sulfamylon Cream - 8.5% | cream | 8.5 % | topical | 07-03-1996 | 20-11-2008 | Canada |
Generic Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Mafenide Acetate | powder, for solution | 50 g/1 | topical | 12-02-2013 | US |
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Sulfamylon | cream | 85 mg/g | topical | 08-12-2006 | US | |
| Sulfamylon | powder, for solution | 50 g/1 | topical | 05-06-1998 | US | |
| Sulfamylon Cream - 8.5% | cream | 8.5 % | topical | 07-03-1996 | 20-11-2008 | Canada |
Generic Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Mafenide Acetate | powder, for solution | 50 g/1 | topical | 12-02-2013 | US |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Mafenide Acetate | Mafenide |
| Sulfamylon | Mafenide |
| Sulfamylon | Mafenide |
| Sulfamylon Cream - 8.5% | Mafenide |
| Brand Name | Ingredients |
|---|---|
| Mafenide Acetate | Mafenide |
| Sulfamylon | Mafenide |
| Sulfamylon | Mafenide |
| Sulfamylon Cream - 8.5% | Mafenide |
Categories
- No Category
Pharmacology
Indication: Mafenide is indicated in the treatment of severe burns.
Pharmacodynamics: Not Available
Mechanism of action: The precise mechanism of mafenide is unknown. However, mafenide reduces the bacterial population in the avascular burn tissue and promotes spontaneous heeling of deep burns.
Absorption: Mafenide is absorbed through devascularized areas into the systemic circulation following topical administration.
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Renal—Metabolite rapidly excreted in urine in high concentrations; however, the parent compound has not been detected in urine.
Half life: Not Available
Clearance: Not Available
Toxicity: Since mafenide is metabolized to a carbonic anhydrase inhibitor, metabolic acidosis could occur. Mafenide is contraindicated in persons with renal impairment or sulfonamide hypersensitivity.
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: The precise mechanism of mafenide is unknown. However, mafenide reduces the bacterial population in the avascular burn tissue and promotes spontaneous heeling of deep burns.
Absorption: Mafenide is absorbed through devascularized areas into the systemic circulation following topical administration.
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Renal—Metabolite rapidly excreted in urine in high concentrations; however, the parent compound has not been detected in urine.
Half life: Not Available
Clearance: Not Available
Toxicity: Since mafenide is metabolized to a carbonic anhydrase inhibitor, metabolic acidosis could occur. Mafenide is contraindicated in persons with renal impairment or sulfonamide hypersensitivity.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Not Available
Packagers:
- Not Available
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Powder, for solution | topical | 50 g/1 |
| Cream | topical | 85 mg/g |
| Cream | topical | 8.5 % |
| Form | Route | Strength |
|---|---|---|
| Powder, for solution | topical | 50 g/1 |
| Cream | topical | 85 mg/g |
| Cream | topical | 8.5 % |
Prices
| Unit description | Cost | Unit |
|---|
| Unit description | Cost | Unit |
|---|
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| Dapsone | The risk or severity of adverse effects can be increased when Dapsone is combined with Mafenide. |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Mafenide. |
| Prilocaine | The risk or severity of adverse effects can be increased when Mafenide is combined with Prilocaine. |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Mafenide is combined with Sodium Nitrite. |
| Sodium picosulfate | The therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Mafenide. |
| Drug | Interaction |
|---|---|
| Dapsone | The risk or severity of adverse effects can be increased when Dapsone is combined with Mafenide. |
| Nitric Oxide | The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Mafenide. |
| Prilocaine | The risk or severity of adverse effects can be increased when Mafenide is combined with Prilocaine. |
| Sodium Nitrite | The risk or severity of adverse effects can be increased when Mafenide is combined with Sodium Nitrite. |
| Sodium picosulfate | The therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Mafenide. |
Food Interactions:
- Not Available
Taxonomy
Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Aminosulfonyl compounds
- Aralkylamines
- Benzylamines
- Hydrocarbon derivatives
- Monoalkylamines
- Phenylmethylamines
- Sulfonamides
substituent:
- Amine
- Aminosulfonyl compound
- Aralkylamine
- Aromatic homomonocyclic compound
- Benzenesulfonamide
- Benzylamine
- Hydrocarbon derivative
- Organonitrogen compound
- Organosulfur compound
- Phenylmethylamine
- Primary aliphatic amine
- Primary amine
- Sulfonamide
- Sulfonic acid derivative
- Sulfonyl
References
Synthesis Reference: U.S. Patent 2,288,531.
General Reference: # Maghsoudi H, Salehi F, Khosrowshahi MK, Baghaei M, Nasirzadeh M, Shams R: Comparison between topical honey and mafenide acetate in treatment of burn wounds. Ann Burns Fire Disasters. 2011 Sep 30;24(3):132-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22396671
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # Maghsoudi H, Salehi F, Khosrowshahi MK, Baghaei M, Nasirzadeh M, Shams R: Comparison between topical honey and mafenide acetate in treatment of burn wounds. Ann Burns Fire Disasters. 2011 Sep 30;24(3):132-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22396671
External Links:
| Resource | Link |
|---|---|
| Drugs.com | http://www.drugs.com/international/Mafenide.html |
| Resource | Link |
|---|---|
| Drugs.com | http://www.drugs.com/international/Mafenide.html |
ATC Codes:
- Array
AHFS Codes:
- Not Available
MSDS: Download